Invention Grant
![3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer](/docs/US/2017-05-09/US09643964B2/abs.jpg.600x600.jpg)
- Patent Title: 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer
-
Application No.: US14786338Application Date: 2014-04-24
-
Publication No.: US09643964B2Publication Date: 2017-05-09
- Inventor: George Hynd , Stephen Price , Janusz Kulagowski , Calum MacLeod , Samuel Edward Mann , Terry Aaron Panchal , Patrizia Tisselli , John Gary Montana
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Priority: EP13165167 20130424; EP13186116 20130926
- International Application: PCT/EP2014/058361 WO 20140424
- International Announcement: WO2014/174021 WO 20141030
- Main IPC: A61K31/506
- IPC: A61K31/506 ; C07D471/04
![3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer](/abs-image/US/2017/05/09/US09643964B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
Public/Granted literature
Information query
IPC分类:
